Monoaminergic activity enhancer site (MAE site)

The monoaminergic activity enhancer (MAE) site is a specialized regulatory site located on the axonal terminals of monoaminergic neurons, first characterized by Joseph Knoll (Knoll et al., 1999). Unlike traditional stimulants or reuptake inhibitors, substances acting on this site do not trigger neurotransmitter release directly; instead, they increase the amount of neurotransmitter released in response to an action potential (Miklya, 2016). This mechanism, known as enhancer sensitivity, allows for the potentiation of catecholaminergic and serotoninergic signaling without the risk of depleting neurotransmitter stores or causing the rebound effects associated with amphetamines. Drugs targeting this site, such as BPAP and PPAP, have shown potential in treating neurodegenerative diseases and depression by maintaining the physiological rhythm of neuronal firing while boosting signal intensity (Knoll, 2001). While the functional pharmacology is well-documented in peer-reviewed literature, the specific molecular structure or protein identity of this site remains to be fully elucidated, often leading to its description as an unknown or uncharacterized site.

Other names

Catecholaminergic activity enhancer siteSerotoninergic activity enhancer siteCAE siteSAE siteKnoll's enhancer siteEnhancer site

Enhances the impulse-propagation mediated release of catecholamines and serotonin by increasing the efficiency of the coupling between the action potential and the release of the neurotransmitter pool (Knoll, 1998).